Skip to main content

News in Psoriasis

ALN
October 27, 2020
Dermatologists, gastroenterologists, and rheumatologists completed a questionnaire so that researchers could gauge clinicians’ experience with oral, intramuscular, and intra-articular corticosteroids in the treatment of patients with psoriasis.
The Dermatologist
September 11, 2020
Results from a recent study suggested a possible increased risk of serious cardiovascular events among patients with high cardiovascular risk before initiating ustekinumab.
ALN
July 24, 2020
Findings from a recent analysis of phase 3 AMAGINE-2 and AMAGINE-3 trials showed greater benefit with brodalumab compared with ustekinumab for patients with psoriasis.
The Dermatologist
June 09, 2020
A recent study demonstrated the safety and long-term effectiveness of bimekizumab, with participants maintaining high PASI scores through 60 weeks of treatment.
ALN
February 14, 2020
In a recent study, researchers investigated whether dose reduction of biologics was noninferior to usual care among patients with well-controlled plaque psoriasis.
The Dermatologist
January 14, 2020
Results from a small retrospective study suggest adding apremilast to biologic therapy may be a safe and effective option for biologic fatigue among patients with psoriasis.
The Dermatologist
December 05, 2019
In a recent study that assessed the impact of metabolic conditions on health care costs and treatment outcomes for biologics and apremilast, the researchers found patients with psoriasis and metabolic conditions had higher rates of switching and discontinuation.
The Dermatologist
November 22, 2019
A recent nationwide population-based cohort study investigated the impact of body weight variability on the risk of developing psoriasis.
The Dermatologist
August 16, 2019
A phase 3, multicenter, randomized, controlled trial compared the efficacy of guselkumab with secukinumab for achieving PASI 90 after 48 weeks of treatment.
The Dermatologist
August 12, 2019
A recent study investigated whether tumor necrosis factor inhibitors, anti-IL-12/23 and anti-IL-17 inhibitors affected body weight and body mass index among patients with psoriasis.
Back to Top